Statistics

Total Visits

Views
Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer45

Select a period of time:

Number of views in the range

Views
Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer16

Views

Views
June 20250
July 20254
August 20250
September 202510
October 20251
November 20250
December 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States12
Brazil2
Senegal1
Turkey1
 

Top cities views

Views
Dallas11
Beltsville1
Dakar1
Santa Bárbara d'Oeste1
Telêmaco Borba1